[18F]DPA-714:合并用药、年龄、性别、BMI和TSPO多态性对人血浆输入函数的影响
在201例接受脑部和全身PET显像的受试者中评估合并用药、年龄、性别、BMI及TSPO亲和力状态对[18F]DPA-714代谢和血浆药代动力学的影响。CYP3A4抑制剂或诱导剂等合并用药以及TSPO基因状态、年龄、BMI和性别主要贡献放射性示踪剂代谢和/或浓度的个体间变异,可能影响[18F]DPA-714的输入函数及其人脑和外周摄取。
要点
- 动脉与静脉[18F]DPA-71470-90和SUV70-90无显著差异,故相关性分析采用静脉血浆。
- 47例接受CYP3A4抑制剂或诱导剂合并用药的受试者出现[18F]DPA-71470-90大幅升高(至88%)或降低(至23%)及SUV70-90值2-3倍变化。
- 未考虑个体代谢率导致VT值偏差约30%。
核心结论
- 任何抑制或诱导CYP3A4的合并用药以及TSPO基因状态、年龄、BMI和性别主要贡献放射性示踪剂代谢和/或浓度的个体间变异,可能影响[18F]DPA-714的输入函数及其人脑和外周摄取。
研究设计与样本
- 在201例接受脑部和全身PET显像以研究神经炎症在神经系统疾病中作用的受试者中开展研究,包括138例患者和63例健康对照(HCs),其中16例受试者额外进行动脉采血。
- 在90分钟脑PET采集期间,采用直接固相萃取法估算138例患者和63例健康对照静脉血浆中[18F]DPA-714的非代谢分数。
主要发现
- 动脉与静脉[18F]DPA-71470-90和SUV70-90无显著差异,故采用静脉血浆进行相关性分析。
- 患者与健康对照的[18F]DPA-71470-90无显著差异(59.7 ± 12.3% vs 60.2 ± 12.9%),但个体间变异大。
- 47例接受CYP3A4抑制剂或诱导剂合并用药的受试者出现[18F]DPA-71470-90大幅升高(至88%)或降低(至23%)及SUV70-90值2-3倍变化。
- 使用个体输入函数(VTIND)与源自未治疗健康对照的群体输入函数(VTPBIF)计算的皮层-血浆比值比较表明,未考虑个体代谢率导致VT值偏差约30%。
- 无上述合并用药受试者的多元线性回归模型分析提示[18F]DPA-71470-90与年龄、BMI和性别显著相关,而TSPO多态性不影响放射性示踪剂代谢;[18F]DPA-714代谢随年龄和BMI下降,女性显著快于男性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed to assess the effect of concomitant medication, age, sex, body mass index and 18-kDa translocator protein (TSPO) binding affinity status on the metabolism and plasma pharmacokinetics of [18F]DPA-714 and their influence on the plasma input function in a large cohort of 201 subjects who underwent brain and whole-body PET imaging to investigate the role of neuroinflammation in neurological diseases. METHODS: The non-metabolized fraction of [18F]DPA-714 was estimated in venous plasma of 138 patients and 63 healthy controls (HCs; including additional arterial sampling in 16 subjects) during the 90 min brain PET acquisition using a direct solid-phase extraction method. The mean fraction between 70 and 90 min post-injection ([18F]DPA-71470-90) and corresponding normalized plasma concentration (SUV70-90) were correlated with all factors using a multiple linear regression model. Differences between groups (arterial vs venous measurements; HCs vs patients; high- (HAB), mixed- (MAB) and low-affinity binders (LAB); subjects with vs without co-medications, females vs males were also assessed using the non-parametric Mann-Whitney or Kruskal-Wallis ANOVA tests. Finally, the impact of co-medications on the brain uptake of [18F]DPA-714 at equilibrium was investigated. RESULTS: As no significant differences were observed between arterial and venous [18F]DPA-71470-90 and SUV70-90, venous plasma was used for correlations. [18F]DPA-71470-90 was not significantly different between patients and HCS (59.7 ± 12.3% vs 60.2 ± 12.9%) despite high interindividual variability. However, 47 subjects exhibiting a huge increase or decrease of [18F]DPA-71470-90 (up to 88% or down to 23%) and SUV70-90 values (2-threefold) were found to receive co-medications identified as inhibitors or inducers of CYP3A4, known to catalyse [18F]DPA-714 metabolism. Comparison between cortex-to-plasma ratios using individual input function (VTIND) or population-based input function derived from untreated HCs (VTPBIF) indicated that non-considering the individual metabolism rate led to a bias of about 30% in VT values. Multiple linear regression model analysis of subjects free of these co-medications suggested significant correlations between [18F]DPA-71470-90 and age, BMI and sex while TSPO polymorphism did not influence the metabolism of the radiotracer. [18F]DPA-714 metabolism fell with age and BMI and was significantly faster in females than in males. Whole-body PET/CT exhibited a high uptake of the tracer in TSPO-rich organs (heart wall, spleen, kidneys…) and those involved in metabolism and excretion pathways (liver, gallbladder) in HAB and MAB with a strong decrease in LAB (-89% and -85%) resulting in tracer accumulation in plasma (4.5 and 3.3-fold increase). CONCLUSION: Any co-medication that inhibits or induces CYP3A4 as well as TSPO genetic status, age, BMI and sex mostly contribute to interindividual variations of the radiotracer metabolism and/or concentration that may affect the input function of [18F]DPA-714 and consequently its human brain and peripheral uptake. TRIAL REGISTRATION: INFLAPARK, NCT02319382, registered December 18, 2014, retrospectively registered; IMABIO 3, NCT01775696, registered January 25, 2013, retrospectively registered; INFLASEP, NCT02305264, registered December 2, 2014, retrospectively registered; EPI-TEP, EudraCT 2017-003381-27, registered September 24, 2018.
引用
- Peyronneau MA, Kuhnast B, Nguyen DL, et al. [18F]DPA-714: Effect of co-medications, age, sex, BMI and TSPO polymorphism on the human plasma input function. Eur J Nucl Med Mol Imaging. 2023. PMID: 37291448. doi:10.1007/s00259-023-06286-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。